

For brokers and producers only

Date: November 12, 2020

Markets: All (except FEP and Medicare Supplement members)

2020 Rx Enhancements

Medical Pharmacy Management (MPM)

Effective **January 1, 2021**, the medications listed below covered under the medical benefit will require prior authorization and/or site of care to better manage rising specialty drug costs. Impacted members will be notified via letter by December 1 and providers were notified in the October issue of BlueLink.

Prior authorization is required to ensure safe and effective use of these high-cost medications. Through prior authorization, site of care criteria is applied for selected medications as an opportunity to help reduce overall health care costs without compromising quality of care. The outpatient hospital setting is generally recognized as one of the most costly options for specialty infusions with costs up to three times higher compared to non-hospital settings.

To view a full list of medications covered under the medical benefit that require prior authorization or subject to site of care, visit the [Specialty Drug List](#). This list is updated monthly.

Prior Authorization

Failure to obtain prior authorization for these drugs may result in the denial of the claim payment.

Drug Name	Drug Class	Drug Name	Drug Class
Blenrep	Oncology	Udenyca	Neutropenia
Cablivi	Thrombocytopenia	Viltepsa	Rare disorders
Darzalex Faspro	Oncology	Vyepti	Migraine
Monjuvi	Oncology	Zarxio	Neutropenia
Synribo	Oncology	Ziextenzo	Neutropenia
Tecartus	Oncology		

Site of Care

Coverage for these medications at an outpatient hospital setting is approved only if medical necessity criteria are met at the time of prior authorization. Members have the option to receive their infusion at an alternate site including their home, an ambulatory infusion center or a physician's office.

Drug Name	Drug Class
Vyepi	Migraine

For more information

Please contact your broker sales representative.